Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Renal disease

Renal damage

Adenosine A2 receptor (ADORA2)

In vitro and mouse studies suggest ADORA2 agonist-treated dendritic cells (DCs) could help treat acute kidney injury. Mice with Adora2-/- DCs showed greater susceptibility to kidney injury than mice with DCs deficient in other adenosine receptors. In wild-type mice, ADORA2 agonist-treated DCs given before or 1-6 hours after kidney injury protected kidney function, whereas untreated DCs did not. Next steps could include optimizing the cell-based therapy protocol.
Addex Therapeutics Ltd.'s A2A PAM, a positive allosteric modulator of ADORA2, is in discovery stages to treat psoriasis and osteoarthritis.

SciBX 5(43); doi:10.1038/scibx.2012.1146
Published online Nov. 1, 2012

Patent and licensing status unavailable

Li, L. et al. J. Clin. Invest.; published online Oct. 24, 2012;
doi:10.1172/JCI63170
Contact: Li Li, University of Virginia, Charlottesville, Va.
e-mail:
ll3m@virginia.edu